vs
LIGAND PHARMACEUTICALS INC（LGND）与RESOURCES CONNECTION, INC.（RGP）财务数据对比。点击上方公司名可切换其他公司
RESOURCES CONNECTION, INC.的季度营收约是LIGAND PHARMACEUTICALS INC的2.0倍（$117.7M vs $59.7M），LIGAND PHARMACEUTICALS INC净利率更高（75.1% vs -10.8%，领先85.8%），LIGAND PHARMACEUTICALS INC同比增速更快（39.4% vs -19.2%），LIGAND PHARMACEUTICALS INC自由现金流更多（$45.9M vs $15.6M），过去两年LIGAND PHARMACEUTICALS INC的营收复合增速更高（38.8% vs -11.8%）
利根制药是美国的生物制药企业，专注于收购和开发可产生特许权使用费的资产。截至2024年，公司的资产组合涵盖约90款覆盖多个治疗领域的药品的特许权使用权，可从多发性骨髓瘤治疗药物凯洛斯、Evomela，肾病治疗药物Filspari，以及肺炎球菌疫苗Vaxneuvance等知名产品中获得相关收益。
RGP原名 Resources Global Professionals，是 Resources Connection, Inc. 的核心运营主体，面向全球客户提供多领域专业咨询服务，覆盖财务会计、信息管理、治理风险合规、人力资本、法务监管、企业咨询与重组、战略传播以及供应链管理等板块。
LGND vs RGP — 直观对比
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $59.7M | $117.7M |
| 净利润 | $44.8M | $-12.7M |
| 毛利率 | — | 37.1% |
| 营业利润率 | 23.2% | -10.3% |
| 净利率 | 75.1% | -10.8% |
| 营收同比 | 39.4% | -19.2% |
| 净利润同比 | 244.1% | 81.6% |
| 每股收益（稀释后） | $2.42 | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $59.7M | $117.7M | ||
| Q3 25 | $115.5M | $120.2M | ||
| Q2 25 | $47.6M | $139.3M | ||
| Q1 25 | $45.3M | $129.4M | ||
| Q4 24 | $42.8M | $145.6M | ||
| Q3 24 | $51.8M | $136.9M | ||
| Q2 24 | $41.5M | $148.2M | ||
| Q1 24 | $31.0M | $151.3M |
| Q4 25 | $44.8M | $-12.7M | ||
| Q3 25 | $117.3M | $-2.4M | ||
| Q2 25 | $4.8M | $-73.3M | ||
| Q1 25 | $-42.5M | $-44.1M | ||
| Q4 24 | $-31.1M | $-68.7M | ||
| Q3 24 | $-7.2M | $-5.7M | ||
| Q2 24 | $-51.9M | $10.5M | ||
| Q1 24 | $86.1M | $2.5M |
| Q4 25 | — | 37.1% | ||
| Q3 25 | — | 39.5% | ||
| Q2 25 | — | 40.2% | ||
| Q1 25 | — | 35.1% | ||
| Q4 24 | — | 38.5% | ||
| Q3 24 | — | 36.5% | ||
| Q2 24 | — | 40.2% | ||
| Q1 24 | — | 37.0% |
| Q4 25 | 23.2% | -10.3% | ||
| Q3 25 | 47.6% | -1.7% | ||
| Q2 25 | 17.7% | -47.0% | ||
| Q1 25 | -79.9% | -38.4% | ||
| Q4 24 | -22.5% | -52.7% | ||
| Q3 24 | 6.1% | -3.5% | ||
| Q2 24 | -46.0% | 7.6% | ||
| Q1 24 | 9.6% | 2.8% |
| Q4 25 | 75.1% | -10.8% | ||
| Q3 25 | 101.6% | -2.0% | ||
| Q2 25 | 10.2% | -52.6% | ||
| Q1 25 | -93.6% | -34.0% | ||
| Q4 24 | -72.6% | -47.2% | ||
| Q3 24 | -13.8% | -4.2% | ||
| Q2 24 | -125.0% | 7.1% | ||
| Q1 24 | 278.1% | 1.7% |
| Q4 25 | $2.42 | $-0.38 | ||
| Q3 25 | $5.68 | $-0.07 | ||
| Q2 25 | $0.24 | $-2.21 | ||
| Q1 25 | $-2.21 | $-1.34 | ||
| Q4 24 | $-1.70 | $-2.08 | ||
| Q3 24 | $-0.39 | $-0.17 | ||
| Q2 24 | $-2.88 | $0.31 | ||
| Q1 24 | $4.75 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $733.5M | $89.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.0B | $194.6M |
| 总资产 | $1.6B | $289.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $733.5M | $89.8M | ||
| Q3 25 | $664.5M | $77.5M | ||
| Q2 25 | $245.0M | $86.1M | ||
| Q1 25 | $208.9M | $72.5M | ||
| Q4 24 | $256.2M | $78.2M | ||
| Q3 24 | $219.6M | $89.6M | ||
| Q2 24 | $226.9M | $108.9M | ||
| Q1 24 | $310.6M | $113.8M |
| Q4 25 | $1.0B | $194.6M | ||
| Q3 25 | $950.2M | $206.4M | ||
| Q2 25 | $828.5M | $207.1M | ||
| Q1 25 | $795.5M | $277.8M | ||
| Q4 24 | $830.4M | $325.7M | ||
| Q3 24 | $841.2M | $407.2M | ||
| Q2 24 | $775.2M | $418.8M | ||
| Q1 24 | $806.5M | $414.9M |
| Q4 25 | $1.6B | $289.3M | ||
| Q3 25 | $1.5B | $287.2M | ||
| Q2 25 | $948.6M | $304.7M | ||
| Q1 25 | $905.4M | $375.6M | ||
| Q4 24 | $941.8M | $424.9M | ||
| Q3 24 | $954.9M | $512.9M | ||
| Q2 24 | $866.4M | $510.9M | ||
| Q1 24 | $913.9M | $523.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.9M | $15.9M |
| 自由现金流经营现金流 - 资本支出 | $45.9M | $15.6M |
| 自由现金流率自由现金流/营收 | 76.9% | 13.2% |
| 资本支出强度资本支出/营收 | 0.0% | 0.3% |
| 现金转化率经营现金流/净利润 | 1.03× | — |
| 过去12个月自由现金流最近4个季度 | $48.9M | $24.3M |
8季度趋势，按日历期对齐
| Q4 25 | $45.9M | $15.9M | ||
| Q3 25 | $13.1M | $-7.8M | ||
| Q2 25 | $15.8M | $16.8M | ||
| Q1 25 | $-25.4M | $659.0K | ||
| Q4 24 | $28.5M | $1.8M | ||
| Q3 24 | $36.5M | $-309.0K | ||
| Q2 24 | $13.3M | $3.2M | ||
| Q1 24 | $18.7M | $20.5M |
| Q4 25 | $45.9M | $15.6M | ||
| Q3 25 | $13.1M | $-8.0M | ||
| Q2 25 | $15.6M | $16.5M | ||
| Q1 25 | $-25.7M | $238.0K | ||
| Q4 24 | $27.8M | $61.0K | ||
| Q3 24 | $35.9M | $-575.0K | ||
| Q2 24 | $12.9M | $3.0M | ||
| Q1 24 | $18.6M | $20.4M |
| Q4 25 | 76.9% | 13.2% | ||
| Q3 25 | 11.3% | -6.6% | ||
| Q2 25 | 32.7% | 11.8% | ||
| Q1 25 | -56.6% | 0.2% | ||
| Q4 24 | 64.8% | 0.0% | ||
| Q3 24 | 69.4% | -0.4% | ||
| Q2 24 | 31.1% | 2.1% | ||
| Q1 24 | 60.1% | 13.5% |
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.4% | 0.2% | ||
| Q1 25 | 0.5% | 0.3% | ||
| Q4 24 | 1.7% | 1.2% | ||
| Q3 24 | 1.2% | 0.2% | ||
| Q2 24 | 1.0% | 0.1% | ||
| Q1 24 | 0.3% | 0.1% |
| Q4 25 | 1.03× | — | ||
| Q3 25 | 0.11× | — | ||
| Q2 25 | 3.26× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.30× | ||
| Q1 24 | 0.22× | 8.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LGND
| Intangible Royalty Assets | $40.7M | 68% |
| Financial Royalty Assets | $9.8M | 16% |
| Material Sales Captisol | $7.8M | 13% |
| Vaxneuvance | $1.4M | 2% |
RGP
| US | $93.7M | 80% |
| Non Us | $24.0M | 20% |
